Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Qingyi Wang, Bin Xie, Shuang Liu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24

Showing 24 citing articles:

MultiNicheNet: a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data
Robin Browaeys, Jeroen Gilis, Chananchida Sang-aram, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 62
Differential Protein Degradation with a Super-Degron Tag and Thalidomide Analogs: EGFP is Degraded in Wild-Type Mouse Cell, While PD-1 Requires CRBN Humanization, Providing New Insights into T Cell Regulation
Chie Naruse, Osamu Ishibashi, Masatoshi Ohgushi, et al.
(2025)
Closed Access
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
MariaLuisa Vigano, Lixing Wang, Alia As’sadiq, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model
Hiroyuki Inoue, Takayuki Hamasaki, Kazuhiko Inoue, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
Xuan-Yu Gu, Jinlong Huo, Yu Zhiyong, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 9-25
Open Access | Times Cited: 4
Ferroptosis-Related Gene MT1G as a Novel Biomarker Correlated With Prognosis and Immune Infiltration in Colorectal Cancer
Bi Peng, Jinwu Peng, Fanhua Kang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 20
Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer
Dingyi Yu, Penghui Yang, Xiaoyan Lu, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China
Pei Zhang, Lingli Zhang, Kai Xu, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 2, pp. 429-438
Closed Access | Times Cited: 2
Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy
Monisha Prasad, Ramya Sekar, Ramadurai Murugan
Oral Oncology Reports (2024) Vol. 9, pp. 100252-100252
Open Access | Times Cited: 2
The Latest Look at PDT and Immune Checkpoints
David Aebisher, Agnieszka Przygórzewska, Dorota Bartusik‐Aebisher
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 7239-7257
Open Access | Times Cited: 2
IFN-γ blockade after genetic inhibition of PD-1 aggravates skeletal muscle damage and impairs skeletal muscle regeneration
Shuzhao Zhuang, Aaron P. Russell, Yifan Guo, et al.
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 7
Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
Caihua Zhu, Bing Dai, Hua Zhan, et al.
Irish Journal of Medical Science (1971 -) (2022) Vol. 192, Iss. 3, pp. 1065-1071
Closed Access | Times Cited: 11
The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants
Jiage Ding, Yanyan Zheng, Gang Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188763-188763
Closed Access | Times Cited: 10
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
Kevinn Eddy, Kajal Gupta, Mohamad Naser Eddin, et al.
JID Innovations (2024) Vol. 4, Iss. 2, pp. 100262-100262
Open Access | Times Cited: 1
Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?
Jiaqiang Wang, Hong Ge, Zhichao Tian
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 385-397
Open Access | Times Cited: 4
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab
Satoshi Katayama, Takehiro Iwata, Tasushi Kawada, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 3, pp. 70.e11-70.e18
Closed Access | Times Cited: 3
PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
Zhichao Tian, Weitao Yao
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
Linlin Wang, Changqi Du, Bing Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Immune and Microbial Signatures Associated with PD-1 Blockade Sensitivity in a Preclinical Model for HPV+ Oropharyngeal Cancer
Jennifer Díaz-Rivera, Michael A. Rodríguez-Rivera, Natalie M. Meléndez-Vázquez, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2065-2065
Open Access
Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma
Agnès Ducoulombier, J. Guigay, Marie‐Christine Etienne‐Grimaldi, et al.
Current Opinion in Oncology (2023) Vol. 35, Iss. 3, pp. 166-177
Closed Access | Times Cited: 1
553 Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma
Renee Morecroft, Jordan Phillipps, George Ansstas
Regular and Young Investigator Award Abstracts (2023), pp. A631-A631
Open Access | Times Cited: 1
The Effect of Different Concentrations of Anti-PD-1 and Anti-PD-L1 Antibodies on the Activity of Immune System Cells in Patients With Non-small Cell Lung Cancer
Aleksandra Bożyk, Kamila Wojas‐Krawczyk, Marcin Nicoś, et al.
Research Square (Research Square) (2023)
Open Access
The Tumor Microenvironment Affects Circulating Tumor Cells Metastasis and the Efficacy of Immune Checkpoint Blockade in Non-small Cell Lung Cancer
Xiuxiu Zhang, Sheng Qiu, Cailian Wang
Current Cancer Drug Targets (2023) Vol. 24, Iss. 1, pp. 2-13
Closed Access
The effect of different concentrations of anti-PD-1 and anti-PD-L1 antibodies on the activity of immune system cells in patients with non-small cell lung cancer
Aleksandra Bożyk, Kamila Wojas‐Krawczyk, Marcin Nicoś, et al.
Oncology in Clinical Practice (2023) Vol. 20, Iss. 2, pp. 124-135
Open Access
Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study
Ying Li, Peng Yang, Xiao Zhou, et al.
Frontiers in Surgery (2022) Vol. 9
Open Access
Page 1

Scroll to top